Literature DB >> 31473607

Six-packed antibodies punch better.

Christoph Rader1, Adrian Wiestner2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31473607      PMCID： PMC6717577          DOI： 10.3324/haematol.2019.224196

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  17 in total

Review 1.  Recombinant polyclonal antibodies: the next generation of antibody therapeutics?

Authors:  John S Haurum
Journal:  Drug Discov Today       Date:  2006-07       Impact factor: 7.851

Review 2.  Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.

Authors:  Ronald P Taylor; Margaret A Lindorfer
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

3.  Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Authors:  Erika M Cook; Margaret A Lindorfer; Hilma van der Horst; Simone Oostindie; Frank J Beurskens; Janine Schuurman; Clive S Zent; Richard Burack; Paul W H I Parren; Ronald P Taylor
Journal:  J Immunol       Date:  2016-07-29       Impact factor: 5.422

4.  A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.

Authors:  John C Byrd; John M Pagel; Farrukh T Awan; Andres Forero; Ian W Flinn; Delva P Deauna-Limayo; Stephen E Spurgeon; Leslie A Andritsos; Ajay K Gopal; John P Leonard; Amy J Eisenfeld; Jeannette E Bannink; Scott C Stromatt; Richard R Furman
Journal:  Blood       Date:  2013-12-31       Impact factor: 22.113

Review 5.  Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Authors:  Louis M Weiner; Rishi Surana; Shangzi Wang
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

6.  The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.

Authors:  Annemiek B van Spriel; Sandra de Keijzer; Alie van der Schaaf; Kate H Gartlan; Mariam Sofi; Amanda Light; Peter C Linssen; Jan B Boezeman; Malou Zuidscherwoude; Inge Reinieren-Beeren; Alessandra Cambi; Fabienne Mackay; David M Tarlinton; Carl G Figdor; Mark D Wright
Journal:  Sci Signal       Date:  2012-11-13       Impact factor: 8.192

7.  Complement is activated by IgG hexamers assembled at the cell surface.

Authors:  Christoph A Diebolder; Frank J Beurskens; Rob N de Jong; Roman I Koning; Kristin Strumane; Margaret A Lindorfer; Marleen Voorhorst; Deniz Ugurlar; Sara Rosati; Albert J R Heck; Jan G J van de Winkel; Ian A Wilson; Abraham J Koster; Ronald P Taylor; Erica Ollmann Saphire; Dennis R Burton; Janine Schuurman; Piet Gros; Paul W H I Parren
Journal:  Science       Date:  2014-03-14       Impact factor: 47.728

8.  A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Authors:  Clive S Zent; Xin Victoria Wang; Rhett P Ketterling; Curtis A Hanson; Edward N Libby; Jacqueline C Barrientos; Timothy G Call; Julie E Chang; Jane J Liu; Alejandro R Calvo; Hillard M Lazarus; Jacob M Rowe; Selina M Luger; Mark R Litzow; Martin S Tallman
Journal:  Am J Hematol       Date:  2016-02-09       Impact factor: 10.047

9.  Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Andrzej Hellmann; Janusz Kloczko; Javier Loscertales; Ewa Lech-Maranda; John M Pagel; Anthony Mato; John C Byrd; Farrukh T Awan; Holger Hebart; Jose A Garcia-Marco; Brian T Hill; Michael Hallek; Amy J Eisenfeld; Scott C Stromatt; Ulrich Jaeger
Journal:  Br J Haematol       Date:  2016-12-15       Impact factor: 6.998

10.  A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

Authors:  Rob N de Jong; Frank J Beurskens; Sandra Verploegen; Kristin Strumane; Muriel D van Kampen; Marleen Voorhorst; Wendy Horstman; Patrick J Engelberts; Simone C Oostindie; Guanbo Wang; Albert J R Heck; Janine Schuurman; Paul W H I Parren
Journal:  PLoS Biol       Date:  2016-01-06       Impact factor: 8.029
View more
  2 in total

Review 1.  Bispecific antibodies in cancer immunotherapy.

Authors:  Christoph Rader
Journal:  Curr Opin Biotechnol       Date:  2019-12-13       Impact factor: 9.740

Review 2.  Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy.

Authors:  Olivia A Diaz Arguello; Hidde J Haisma
Journal:  Cancers (Basel)       Date:  2021-03-27       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.